HEALTH
FDA approves Merck’s RSV shot for infants, ramping up competition with Sanofi and AstraZeneca – CNBC
- FDA approves Merck’s RSV shot for infants, ramping up competition with Sanofi and AstraZeneca CNBC
- Merck Says It Wins US Approval for Shot to Prevent Infant RSV Bloomberg
- U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season Yahoo Finance
- US FDA Approves Merck’s RSV Antibody for Infants U.S. News & World Report
- Merck scores FDA nod for Enflonsia, setting up RSV market battle vs. Sanofi and AstraZeneca’s Beyfortus Fierce Pharma
Source link
